235 related articles for article (PubMed ID: 29926531)
21. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
[TBL] [Abstract][Full Text] [Related]
22. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
23. ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma.
Persson CU; von Stedingk K; Fredlund E; Bexell D; Påhlman S; Wigerup C; Mohlin S
Exp Cell Res; 2020 Mar; 388(2):111845. PubMed ID: 31945318
[TBL] [Abstract][Full Text] [Related]
24. The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma.
Jin Y; Yu X; Du J; Li H; Tang W; Jia C; Zan Y; Chen M; Zhang Y; Yu M; Rong W; Zhou D; Zhuang J
Ann Hematol; 2021 May; 100(5):1251-1260. PubMed ID: 33686491
[TBL] [Abstract][Full Text] [Related]
25. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
Li X; Yang Y; Yi X
Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
[TBL] [Abstract][Full Text] [Related]
26. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib.
Du C; Mao X; Xu Y; Yan Y; Yuan C; Du X; Liu J; Fan H; Wang Q; Sui W; Deng S; Fu M; Li Z; Li C; Zhao J; Yi S; Liu L; Hao M; Zou D; Zhao Y; Qiu L; An G
Leuk Lymphoma; 2020 May; 61(5):1201-1210. PubMed ID: 31842644
[TBL] [Abstract][Full Text] [Related]
27. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
[TBL] [Abstract][Full Text] [Related]
28. Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation.
Xie H; Gu Y; Wang W; Wang X; Ye X; Xin C; Lu M; Reddy BA; Shu P
Sci Rep; 2020 Jan; 10(1):766. PubMed ID: 31964975
[TBL] [Abstract][Full Text] [Related]
29. MgcRacGAP, a cytoskeleton regulator, inhibits HIF-1 transcriptional activity by blocking its dimerization.
Lyberopoulou A; Mylonis I; Papachristos G; Sagris D; Kalousi A; Befani C; Liakos P; Simos G; Georgatsou E
Biochim Biophys Acta; 2013 Jun; 1833(6):1378-87. PubMed ID: 23458834
[TBL] [Abstract][Full Text] [Related]
30. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Zhang L; Pan L; Xiang B; Zhu H; Wu Y; Chen M; Guan P; Zou X; Valencia CA; Dong B; Li J; Xie L; Ma H; Wang F; Dong T; Shuai X; Niu T; Liu T
Oncotarget; 2016 May; 7(21):30876-91. PubMed ID: 27129167
[TBL] [Abstract][Full Text] [Related]
31. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
32. 4S polycyclic aromatic hydrocarbon receptor (glycine N-methyltransferase) and the aryl hydrocarbon receptor nuclear translocator (hypoxia inducible factor-1β) interaction in Chinese hamster ovary and rat hepatoma cells: 4S PAH-R/ARNT hetero-oligomers?
Sterling KM
J Cell Biochem; 2011 Aug; 112(8):2015-8. PubMed ID: 21445860
[TBL] [Abstract][Full Text] [Related]
33. NcoA2-Dependent Inhibition of HIF-1α Activation Is Regulated via AhR.
Tsai CH; Li CH; Liao PL; Cheng YW; Lin CH; Huang SH; Kang JJ
Toxicol Sci; 2015 Dec; 148(2):517-30. PubMed ID: 26350169
[TBL] [Abstract][Full Text] [Related]
34. Non-hypoxic transcriptional activation of the aryl hydrocarbon receptor nuclear translocator in concert with a novel hypoxia-inducible factor-1alpha isoform.
Lee KH; Park JW; Chun YS
Nucleic Acids Res; 2004; 32(18):5499-511. PubMed ID: 15479785
[TBL] [Abstract][Full Text] [Related]
35. Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia.
Salceda S; Beck I; Caro J
Arch Biochem Biophys; 1996 Oct; 334(2):389-94. PubMed ID: 8900415
[TBL] [Abstract][Full Text] [Related]
36. Clock-controlled output gene Dbp is a regulator of Arnt/Hif-1β gene expression in pancreatic islet β-cells.
Nakabayashi H; Ohta Y; Yamamoto M; Susuki Y; Taguchi A; Tanabe K; Kondo M; Hatanaka M; Nagao Y; Tanizawa Y
Biochem Biophys Res Commun; 2013 May; 434(2):370-5. PubMed ID: 23567972
[TBL] [Abstract][Full Text] [Related]
37. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
38. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
Deng P; Zhou YL; Wei YL; Li P; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
[TBL] [Abstract][Full Text] [Related]
40. LDL suppresses angiogenesis through disruption of the HIF pathway via NF-κB inhibition which is reversed by the proteasome inhibitor BSc2118.
Yao G; Zhang Q; Doeppner TR; Niu F; Li Q; Yang Y; Kuckelkorn U; Hagemann N; Li W; Hermann DM; Dai Y; Zhou W; Jin F
Oncotarget; 2015 Oct; 6(30):30251-62. PubMed ID: 26388611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
